T MEM16A is a subunit of calcium-activated chloride channels (CaCCs) in various mammalian tissues. [1][2][3] TMEM16A channels are present in the apical membranes of secretory epithelial cells and are gated open by increases in cytosolic Ca 2+ . [4][5][6] In addition to transepithelial transport and driving epithelial fluid secretion, TMEM16A also participates in a wide range of cell biological functions, including neuronal excitability, vascular tone, gastrointestinal tract motility, nociception, and the metastasis of certain cancers.
T
MEM16A is a subunit of calcium-activated chloride channels (CaCCs) in various mammalian tissues. [1] [2] [3] TMEM16A channels are present in the apical membranes of secretory epithelial cells and are gated open by increases in cytosolic Ca 2+ . [4] [5] [6] In addition to transepithelial transport and driving epithelial fluid secretion, TMEM16A also participates in a wide range of cell biological functions, including neuronal excitability, vascular tone, gastrointestinal tract motility, nociception, and the metastasis of certain cancers. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] TMEM16A is widely expressed in various epithelial cells, smooth muscle cells (SMCs), interstitial cells of Cajal, and nociceptive neurons and is also highly expressed in several tumors. 6 In the cardiovascular system, TMEM16A protein is abundant in vascular smooth muscle cells (VSMCs) and is distributed throughout the cytoplasm in the SMCs of the portal vein, thoracic aorta, carotid artery, and pulmonary artery. [17] [18] [19] TMEM16A is a viable candidate for the native CaCC in this cell type. A recent study showed that TMEM16A expression was upregulated by chronic hypoxia. In particular, pulmonary arterial smooth muscle cells isolated from rats exposed to 10% oxygen for 3 to 4 weeks showed increased CaCC currents and TMEM16A expression as well as increased contractile responses.
10 TMEM16A-dependent CaCC activity was also upregulated during pulmonary hypertension. Moreover, pulmonary arterial smooth muscle cells from animals with pulmonary hypertension revealed an increase in the expression of TMEM16A at the mRNA and protein levels and a parallel alteration in CaCCs. 20 In another study, TMEM16A expression was downregulated in SMCs isolated from the basilar arteries of hypertensive rats compared with normal rats; this downregulation of TMEM16A facilitated cell entrance from the G0/G1 phase to the S phase and thus promoted cell proliferation. 21 In addition, recent studies have supported the important role that Cl − channels play in regulating cell proliferation and cell cycle transition in a variety of cell types. 22, 23 Despite these findings, whether and how TMEM16A is involved in Abstract-The TMEM16A protein is an important component of Ca 2+ -dependent Cl − channels (CaCCs) in vascular smooth muscle cells. A recent study showed that TMEM16A inhibits angiotensin II-induced proliferation in rat basilar smooth muscle cells. However, whether and how TMEM16A is involved in vascular remodeling characterized by vascular smooth muscle cell proliferation remains largely unclear. In this study, luciferase reporter, Western blotting, and qRT-PCR assays were performed. The results suggested that myocardin promotes TMEM16A expression by forming a complex with serum response factor (SRF) on the TMEM16A promoter in human aortic smooth muscle cells (HASMCs). In turn, upregulated TMEM16A promotes expression of myocardin and vascular smooth muscle cell marker genes, thus forming a positive feedback loop that induces cell differentiation and inhibits cell proliferation. Angiotensin II inhibits TMEM16A expression via Krüppel-like factor 5 (KLF5) in cultured HASMCs. Moreover, in vivo experiments show that infusion of angiotensin II into mice causes a marked reduction in TMEM16A expression and vascular remodeling, and angiotensin II-induced effects are largely reversed in KLF5 null (KLF5 −/− ) mice. KLF5 competes with SRF to interact with myocardin, thereby limiting myocardin binding to SRF and the synergistic activation of the TMEM16A promoter by myocardin and SRF. Our studies demonstrated that angiotensin II induces KLF5 expression and facilitates KLF5 association with myocardin to disrupt the myocardin-SRF complex, subsequently leading to inhibition of TMEM16A transcription. Blocking the positive feedback loop between myocardin and TMEM16A may be a novel therapeutic approach for vascular remodel-vascular remodeling characterized by VSMC proliferation remain largely unclear.
Myocardin is a potent transcriptional coactivator expressed exclusively in contractile smooth and cardiac muscle cells. Myocardin does not bind DNA directly. It associates strongly with serum response factor (SRF), a transcription factor that binds to conserved CArG box [CC (A/T) 6 GG] DNA sequences present within the promoters of SMC genes and acts as a weak activator of gene expression, to selectively induce expression of CArGdependent SMC genes, including SM22α and SMα-actin. 24, 25 In this study, we show that myocardin promoted TMEM16A expression by forming a complex with SRF bound to the CArG box of the TMEM16A promoter in human aortic smooth muscle cells (HASMCs). In turn, upregulated TMEM16A promoted expression of myocardin and VSMC marker genes, thus forming a positive feedback loop that induced cell differentiation and inhibited cell proliferation. Angiotensin II (Ang II) induced Krüppel-like factor 5 (KLF5) expression and facilitated KLF5 association with myocardin to disrupt the myocardin-SRF complex, subsequently leading to blockage of this positive feedback loop and inhibition of TMEM16A transcription, thus influencing cellular proliferation.
Methods
An expanded Methods section can be found in the online-only Data Supplement.
Results

Myocardin Upregulates TMEM16A Expression
To identify transcription factors that regulate expression of TMEM16A, we constructed a TMEM16A promoter-luciferase reporter construct, including the region spanning from −2000 to +1 of the human TMEM16A promoter and performed a luciferase assay in 293A cells. Our results indicated that overexpression of SRF or myocardin, but not KLF4, concentration-dependently increased TMEM16A promoter activity ( Figure 1A ). Truncating the TMEM16A promoter sequence from −2000 to −536 did not affect activation of the promoter by SRF. However, further deletion between −536 and −349 dramatically decreased the activation of this reporter by SRF ( Figure 1B , left panel), indicating that the region between −536 and −349 is critical for conferring the capacity to respond to SRF. Indeed, this region contains one TGF-β control element and one SRF-responsive element CArG box ( Figure 1B, right panel) . Coexpression of myocardin and SRF increased activation of the TMEM16A promoter (−2000 to +1 and −536 to +1) ≈2-fold over that seen with myocardin or SRF alone. Truncating the TMEM16A promoter to −349 abolished the synergistic activation of the promoter by myocardin and SRF ( Figure 1C) . Moreover, knockdown of myocardin in HASMCs led to a decrease in TMEM16A protein ( Figure 1D , left panel) and mRNA expression ( Figure 1D , right panel). Taken together, these results indicate that myocardin and SRF are necessary for TMEM16A expression in HASMCs.
TMEM16A Induces VSMC Differentiation and Inhibits VSMC Proliferation
To investigate the function of TMEM16A in VSMCs, adenoviruses encoding TMEM16A (Ad-GFP-TMEM16A) or GFP control (Ad-GFP) were transduced into HASMCs and mouse aortic smooth muscle cells. Voltage patch clamp experiments showed that HASMCs infected with Ad-GFP-TMEM16A exhibited much larger CaCC currents than those infected with Ad-GFP (Figure 2A ). Western blot analysis showed that overexpression of TMEM16A in HASMCs significantly increased the expression of the VSMC differentiation markers SM22α and SMα-actin and decreased proliferating cell nuclear antigen (PCNA) and cyclin D1 levels in a time-and dose-dependent manner ( Figure 2B ). Similar results were obtained in mouse aortic smooth muscle cells ( Figure 2C ). By contrast, using 2 distinct siRNAs to silence TMEM16A expression led to elevated protein levels of PCNA and cyclin D1 and decreased protein levels of SM22α and SMα-actin in HASMCs ( Figure 2D ). Moreover, forced expression of TMEM16A in HASMCs also markedly increased SM22α and SMα-actin mRNA expression and inhibited cyclin D1 mRNA expression and cell proliferation ( Figure 2E ). To further validate the effect of TMEM16A on VSMC proliferation in vivo, we re-expressed GFP or TMEM16A using adenovirus-mediated gene transfer. Mice were subjected to endothelial denudation by wire injury to the femoral artery followed by intraluminal instillation with adenoviruses for 20 minutes and were examined 14 days later. As shown in Figure 2F and Figure S1 in the online-only Data Supplement, overexpression of TMEM16A largely reduced the neointimal area and medial proliferative cell number compared with the Ad-GFP-treated control mice. Because VSMC proliferation plays a key role in neointima formation after vascular injury, we conclude that expression of TMEM16A can inhibit VSMC proliferation in vivo, thus leading to reduced neointima formation after vascular injury.
TMEM16A Induces VSMC Differentiation and Inhibits VSMC Proliferation via Upregulating Myocardin Expression
To understand how TMEM16A regulates VSMC differentiation and proliferation, we detected the expression of a series of transcription factors responsible for VSMC differentiation and proliferation in HASMCs infected with Ad-TMEM16A. Interestingly, overexpression of TMEM16A markedly induced the mRNA and protein expression of myocardin but not KLF4, KLF5, and SRF ( Figure 3A and 3B). Conversely, knockdown of TMEM16A by either of the 2 siRNAs targeting TMEM16A decreased expression of myocardin ( Figure 3C ). These data indicate that TMEM16A specifically induces the expression of myocardin and that myocardin forms a positive feedback loop with TMEM16A to induce VSMC differentiation and inhibit VSMC proliferation ( Figure 3D ).
TMEM16A protein expression while increasing the protein expression of its known target genes KLF5, cyclin D1, and NOX-1 in a time-and dose-dependent manner. Similarly, Ang II also decreased TMEM16A mRNA expression in a time-and dose-dependent manner in HASMCs ( Figure 4B ). Ang II treatment also significantly inhibited TMEM16A protein expression in mouse aortic smooth muscle cells but not in human cardiac microvascular endothelial cells ( Figure 4C ). Consistent with these results, Western blot analysis also showed decreased expression of TMEM16A in the thoracic aorta of human angiotensinogen transgenic mice compared with wild-type (WT) mice ( Figure 4D ). In addition, overexpression of TMEM16A largely blocked Ang II-induced upregulation of cyclin D1 and PCNA and abrogated Ang II-induced downregulation of SM22α and SMα-actin ( Figure 4E , left panel). BrdU incorporation also showed that overexpression of TMEM16A largely abolished Ang II-induced cell proliferation ( Figure 4E , right panel). These findings demonstrate that Ang II downregulates TMEM16A expression and disrupts the positive feedback loop between TMEM16A and myocardin, subsequently leading to cell proliferation.
Ang II Inhibits TMEM16A Expression via KLF5
Because KLF5 is known to mediate Ang II-induced gene expression, 26, 27 we sought to investigate whether KLF5 mediated Ang II-induced suppression of TMEM16A expression. The overexpression of KLF5 in HASMCs infected with adenovirus encoding KLF5 (Ad-GFP-KLF5) significantly decreased TMEM16A protein expression and increased cyclin D1 protein expression in a time-and dose-dependent manner ( Figure 5A , left and middle panels). Accordingly, KLF5 overexpression also markedly inhibited TMEM16A mRNA expression ( Figure 5A , right panel). However, overexpression of KLF4 in HASMCs had no significant effect on expression levels of TMEM16A protein or mRNA ( Figure 5B ). In addition, when HASMCs were transfected with KLF5-specific siRNA (siKLF5) to block endogenous KLF5 expression, Ang II-mediated suppression of TMEM16A protein and mRNA ) and one CArG box (right panel). C, 293A cells were transfected with the indicated TMEM16A promoter luciferase reporters alone or in combination with SRF and Myoc expression vectors. Cells were lysed, and the luciferase activity was measured using the dual luciferase reporter assay system. The data represent the relative TMEM16A promoter activity normalized to Renilla luciferase. Error bars represent the SD of 3 independent experiments. *P<0.05 vs the pcDNA3.1 group. D, Human aortic smooth muscle cells (HASMCs) were mock-transfected (−) or transfected with siRNA targeting Myoc (siMyoc) or a control siRNA (siCon). 24 hours after transfection, Myoc and TMEM16A levels were determined via immunoblotting (left panel). GAPDH was used as a control for equal loading in all experiments. The relative expression of TMEM16A mRNA was examined using qRT-PCR and presented after normalizing to GAPDH (mean±SD; n=3; right panel). *P<0.05 vs the mocktransfected group. by guest on August 30, 2017 http://hyper.ahajournals.org/ Downloaded from expression was abrogated ( Figure 5C ). Simultaneously, the inhibitory effect of Ang II on TMEM16A protein expression was increased by KLF5 overexpression ( Figure 5D ). Further studies were performed in KLF5 null (KLF5 −/− ) and WT mice infused with or without Ang II. As shown in Figure 6A , a marked medial expansion was observed in the thoracic aorta of WT mice 28 days after Ang II infusion, and this expansion was strongly reduced in KLF5 −/− mice. In addition, Ang II infusion promoted a marked increase in the density of nuclei and the number of proliferating Ki-67 + SMCs in the media . The current densities vs holding voltage relationship from experiments shown in left and middle panels (right panel; n=5-8). B, Ad-GFP-TMEM16A were used to infect HASMCs at the indicated doses and for the indicated times. Protein was isolated, and NOX-1, p47 phox , cyclin D1, SM22α, SMα-actin, proliferating cell nuclear antigen (PCNA), and GAPDH expression levels were measured via immunoblotting. C, Mouse aortic smooth muscle cells (MASMCs) were infected with Ad-GFP or Ad-GFP-TMEM16A for the indicated periods of time. Protein was isolated, and cyclin D1, SM22α, SMα-actin, PCNA, and GAPDH expression levels were measured via immunoblotting. D, HASMCs were transfected with 2 independent siRNAs targeting TMEM16A. 24 hours after transfection, cyclin D1, SM22α, SMα-actin, PCNA, TMEM16A, and GAPDH protein levels were determined via immunoblotting. E, HASMCs were infected with Ad-GFP or Ad-GFP-TMEM16A for the indicated periods of time. SM22α, SMα-actin, and cyclin D1 mRNA levels were assessed using qRT-PCR, and cell proliferation was tested using the bromodeoxyuridine (BrdU) incorporation assay. Error bars represent the SD of 3 independent experiments. *P<0.05 vs the group infected with Ad-GFP. F, Hematoxylin and eosin (HE) staining of representative sections of the femoral arteries of mice 14 days after wire injury, from mice transduced with Ad-GFP (n=4) or Ad-GFP-TMEM16A (n=6). White arrowheads, internal elastic lamina; Black arrowheads, external elastic lamina, defining the borders of the intima and media (left panel). Quantification of cross-sectional neointimal area and media/total vessel area ratio (right panel). Data are presented as mean±SD. *P<0.05 vs the group infected with Ad-GFP. of the thoracic aorta, and KLF5 deficiency ablated the stimulatory effect of Ang II on cell proliferation ( Figure 6B and Figure S2 ). Moreover, Ang II infusion resulted in a marked decrease in TMEM16A expression in the thoracic aorta of WT mice, and this inhibitory effect was blocked by KLF5 deficiency ( Figure 6C ). By contrast, KLF5 expression was strongly induced by Ang II infusion in the thoracic aorta of WT mice and was undetected in KLF5 −/− mice ( Figure 6D ). Overexpression of KLF5 significantly increased cyclin D1 and PCNA expression and decreased SM22α and SMα-actin expression in HASMCs. However, the effects of KLF5 overexpression were completely abrogated by TMEM16A overexpression ( Figure 6E ). These data suggest that Ang II inhibits TMEM16A expression via KLF5 and that TMEM16A reduction is responsible for Ang II-induced vascular remodeling.
Ang II Inhibits TMEM16A Expression by Promoting the Binding of KLF5 to Myocardin
As shown in Figure 7A , KLF5 overexpression dose-dependently inhibited TMEM16A promoter activity. Progressive deletion of the TMEM16A promoter sequence from −2000 to −536 significantly suppressed activation of the TMEM16A promoter by KLF5, whereas truncating the TMEM16A promoter from −2000 to −349 abolished the inhibitory effect of KLF5 on the promoter (Figure 7B ), suggesting that the region between −536 and −349 is necessary for KLF5 function. These results are consistent with the location of an SRF-responsive region within this promoter. Further, cotransfection of KLF5 with SRF and myocardin significantly inhibited the activation of the TMEM16A promoter reporter by SRF alone and the synergy between SRF and myocardin ( Figure 7C, left panel) . When the TGF-β control element box was mutated, KLF5 could still decrease the activation of the TMEM16A promoter (−536 to +1) by SRF alone and the synergy between SRF and myocardin ( Figure 7C, middle panel) . By contrast, following CArG box mutation, neither transfection of SRF alone nor cotransfection of SRF and myocardin, regardless of the presence or absence of KLF5, could activate the TMEM16A promoter (−536 to +1; Figure 7C , right panel). These data strongly suggest that the CArG box contained in the −536 to −349 region is required for the activation of the TMEM16A promoter by SRF alone and the synergy between myocardin and SRF and that the repression of the promoter activity by KLF5 also depends on this CArG box. In addition, a coimmunoprecipitation assay showed that Ang II time-dependently promoted the interaction of KLF5 with myocardin and disrupted the association of myocardin with SRF ( Figure 7D and  7E ). These studies indicate that Ang II-induced KLF5 competes with SRF to interact with myocardin, thereby limiting myocardin binding to SRF and synergistic activation of the TMEM16A promoter by myocardin and SRF.
Discussion
Sequence analysis of the human TMEM16A promoter region spanning from −2000 to +1 indicated that there are several potential binding sites for transcription factors, including SRF, Sp1, KLF, and NF-κB. We then performed a luciferase assay and found that the overexpression of SRF, but not KLF4, Sp1, and NF-κB, increased TMEM16A promoter activity ( Figure 1A and data not shown) . Myocardin, known Figure 1C, left panel) . Because myocardin is known to be a key transcription factor in SMC differentiation, 24, 25 discovering that myocardin upregulated TMEM16A expression prompted us to test whether TMEM16A affected VSMC proliferation and differentiation. We found that TMEM16A markedly increased the expression of the VSMC differentiation markers SM22α and SMα-actin and decreased PCNA and cyclin D1 levels and cell proliferation (Figure 2B-2E) . Moreover, an in vivo animal experiment showed that TMEM16A largely attenuated the neointimal area and medial proliferative cell number after vascular injury ( Figure 2F and Figure S1 ). These results suggest that the overexpression of TMEM16A can inhibit VSMC proliferation in vivo, thus leading to reduced neointima formation after vascular injury. Indeed, Cl − channels have been found to play a key role in the regulation of cell cycle progression and cell proliferation in a variety of cell types. 22, 23 In particular, a recent study showed that the TMEM16A CaCC acts as a negative regulator of cell proliferation by arresting the cell cycle at the G0/G1 phase via a reduction in cyclin D1 and cyclin E expression. 21 However, how TMEM16A regulates VSMC ) were incubated in serum-free medium for 24 hours, followed by treatment with Ang II at the indicated doses for the indicated times. A, TMEM16A, TMEM16J, Krüppel-like factor 5 (KLF5), cyclin D1, NOX-1, and GAPDH protein expression levels were measured via immunoblotting. B, The relative expression of TMEM16A mRNA was examined using qRT-PCR and presented after normalizing to GAPDH (mean±SD; n=3). *P<0.05 vs the untreated group. C, Mouse aortic smooth muscle cells (MASMCs) or human cardiac microvascular endothelial cells (HCMECs) were incubated in serum-free medium for 24 hours, followed by treatment with Ang II for the indicated times. TMEM16A and GAPDH protein expression levels were measured via immunoblotting. D, Lysates were prepared from the thoracic aortic tissues of wild-type (WT) mice and human angiotensinogen transgenic (hAGT-Tg) mice (4 mice per group) and immunoblotted using the indicated antibodies. E, HASMCs were infected with Ad-GFP or Ad-GFP-TMEM16A for 24 hours and then exposed to 0 mol/L or 2×10 -7 mol/L Ang II for another 24 hours. The expression levels of cyclin D1, SM22α, SMα-actin, proliferating cell nuclear antigen (PCNA), GAPDH, and GFP were measured via immunoblotting (left panel), and cell proliferation was tested using the BrdU incorporation assay (right panel). *P<0.05 vs the group infected with Ad-GFP alone. #P<0.05 vs the group treated with Ad-GFP and Ang II. differentiation and proliferation remains unknown. We speculated that TMEM16A might regulate the expression of some transcription factors responsible for VSMC differentiation and proliferation. Interestingly, TMEM16A specifically induced the expression of myocardin in HASMCs ( Figure 3A-3C) . Thus, we concluded that myocardin and TMEM16A form a positive feedback loop that induces VSMC differentiation and inhibits VSMC proliferation ( Figure 3D ). Further studies are required to determine how TMEM16A regulates myocardin expression.
Consistent with the results of a previous study that showed Ang II inhibits TMEM16A expression in BASMCs, 21 our study demonstrated that Ang II also decreased TMEM16A protein and mRNA expression in HASMCs (Figure 4 ). These findings demonstrate that Ang II downregulates TMEM16A expression and disrupts the positive feedback loop between TMEM16A and myocardin, subsequently leading to cell proliferation.
KLF5 belongs to the KLF family and plays a key role in VSMC proliferation by regulating the expression of many types of genes involved in cell proliferation and cardiovascular remodeling. 28 Importantly, KLF5 is a target for Ang II signaling and acts as an essential regulator of cardiovascular remodeling induced by Ang II. 29 In this study, in vitro and in vivo experiments showed that KLF5 mediated Ang II-induced suppression of TMEM16A expression (Figures 5 and 6 ). To further understand the mechanism by which KLF5 mediates Ang II-induced suppression of TMEM16A expression, we performed a luciferase assay. We found that KLF5 significantly inhibited the activation of the TMEM16A promoter (left and middle panels) . The relative expression of TMEM16A mRNA was examined using qRT-PCR and presented after normalizing to GAPDH (mean±SD; n=3; right panel). *P<0.05 vs the group infected with Ad-GFP. B, HASMCs were infected with Ad-GFP or an adenoviral vector expressing KLF4 (Ad-GFP-KLF4) as indicated. TMEM16A protein and mRNA levels were detected via immunoblotting (left panel) and qRT-PCR (right panel), respectively. C, HASMCs were transfected with siRNA targeting KLF5 (siKLF5) or siCon for 24 hours and then treated with or without Ang II (2×10 -7 mol/L) for another 24 hours. Western immunoblotting was performed using anti-TMEM16A, anti-KLF5, and anti-GAPDH antibodies (left panel). HASMCs were transfected with siKLF5 or siCon for 24 hours and then treated with or without Ang II (2×10 -7 mol/L) for another 8 hours. TMEM16A mRNA levels were measured using qRT-PCR and presented after normalizing to GAPDH (mean±SD; n=3; right panel). *P<0.05 vs the group transfected with siCon alone. #P<0.05 vs the group treated with siCon and Ang II. by the synergy between SRF and myocardin through the CArG box located in the region between −536 and −349 of the TMEM16A promoter ( Figure 7A-7C) . We proposed that Ang II might trigger the displacement of myocardin from SRF by promoting the interaction of KLF5 with myocardin. As expected, coimmunoprecipitation assays showed that Ang II time-dependently increased the interaction of KLF5 with myocardin and decreased the interaction of myocardin with SRF ( Figure 7D and 7E) . These studies indicate that Ang II-induced KLF5 competes with SRF to interact with myocardin, thereby limiting myocardin binding to SRF and the synergistic activation of the TMEM16A promoter by myocardin and SRF.
Taken together, our studies show that myocardin promotes TMEM16A expression by forming a complex with SRF bound to the CArG box of the TMEM16A promoter in HASMCs and, in turn, upregulated TMEM16A promotes expression of myocardin and VSMC marker genes, thus forming a positive feedback loop that induces cell differentiation and inhibits cell proliferation. Ang II induces KLF5 expression and facilitates KLF5 association with myocardin to disrupt the myocardin-SRF complex, subsequently leading to the inhibition of TMEM16A transcription and the interruption of this positive feedback loop and ultimately influencing cellular proliferation ( Figure 7F ). For the first time, our data provide insight into the molecular mechanism by which TMEM16A participates in Ang II-mediated VSMC proliferation and vascular remodeling.
Perspective
In these studies, we demonstrated that TMEM16A specifically induces the expression of myocardin and that myocardin 
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None. A, A luciferase reporter controlled by the TMEM16A promoter was transfected into 293A cells with a KLF5 expression plasmid. B, 293A cells were transfected with the indicated TMEM16A promoter luciferase reporters either in combination with or without a KLF5 expression plasmid. C, 293A cells were transfected with the indicated TMEM16A promoter-reporter constructs and expression vectors encoding serum response factor (SRF), Myoc, and KLF5 as indicated. Cells were lysed, and luciferase activity was measured using the dual luciferase reporter assay system. The data represent the relative TMEM16A promoter activity normalized to Renilla luciferase. Error bars represent the SD of 3 independent experiments. *P<0.05 vs the group transfected with each reporter construct alone or GFP expression vector; #P<0.05 vs the group transfected with SRF expression vector alone or SRF and Myoc expression vectors. D and E, Human aortic smooth muscle cells (HASMCs) were incubated in serum-free medium for 24 hours, followed by treatment with Ang II for the indicated times. The interaction between Myoc and KLF5 or SRF was examined using reciprocal coimmunoprecipitation (IP) assays. IgG was used as a negative control for immunoprecipitation. Figure 1D . B, Panels are the same as those in Figure 2B . C, Panels are the same as those in Figure 3B . 
